Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Mineralys Therapeutics Q4 EPS $(0.61) Beats $(0.82) Estimate
Mineralys Therapeutics第四季度每股收益美元(0.61美元)超过预期(0.82美元)
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.82) by 25.61 percent. This is a 64.94 percent increase over losses of $(1.74) per share from the same period last year.
Mineralys Therapeutics(纳斯达克股票代码:MLYS)公布的季度亏损为每股0.61美元,比分析师共识估计的美元(0.82美元)高出25.61%。这比去年同期每股亏损1.74美元(1.74美元)增长了64.94%。